Interval analysis demonstrated impressive results in multiple tumor types with overall response rates of 47% in biliary tract cancer,15 56% in anaplastic thyroid cancer,16 33% in high-grade glioma, and 69% in low-grade glioma.17 Additionally, recent studies in metastatic CRC demonstrated prolonged preservation in quality of life in those treated with BRAF inhibitors.18 As such, this further highlights the importance of better assessing BRAFV600E prevalence in expanded cancer types, including non-CRC GI malignancies. The gene discussed is BRAF; the disease is neoplasm.